Galapagos Appoints Dr. Paulo Fontoura as Independent Non-Executive Director
Galapagos NV has announced the appointment of Dr. Paulo Fontoura as an independent non-executive director to its board, effective from February 9, 2026. He replaces Dr. Susanne Schaffert, who left the board on November 1, 2025.
Dr. Paulo Fontoura was appointed by co-option as an independent non-executive director to the board of Galapagos NV, effective February 9, 2026. Dr. Fontoura brings 20 years of experience in the pharmaceutical industry, with deep expertise in neurology, immunology, ophthalmology, and rare diseases. He currently holds the position of Chief Medical Officer at Xaira. Previously, he served as SVP and Global Head at Roche, where he led clinical development in the fields of neuroscience, immunology, ophthalmology, and rare diseases.
Replacement Information
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Dr. Paulo Fontoura replaces Dr. Susanne Schaffert, who effectively left the board on November 1, 2025, as previously announced in the press release dated October 30, 2025.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 1T2026
Key reported figures
Revenue: 6.5M€
Net income: 14.5M€
Guidance from the release
Je suis particulièrement enthousiasmé par les progrès que nous réalisons.
Risks mentioned
Risque que la transaction avec Gilead ne soit pas finalisée dans les délais prévus.
Risques liés à la disponibilité des ressources financières pour des transactions stratégiques.
Incertitude liée aux coûts de restructuration d'environ 125 millions d'euros à 175 millions d'euros.
Opportunities identified
Opportunité de finaliser la collaboration avec Gilead au deuxième trimestre 2026.
Possibilité de dépenses jusqu'à 500 millions USD pour le développement commercial.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
